Compare Seagate Technology Holdings PLC (STX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Seagate Technology Holdings PLC vs TG Therapeutics Inc — how do they compare? Seagate Technology Holdings PLC trades at $780.55 (market cap $176.19B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Seagate Technology Holdings PLC is far larger — about 21.6× TG Therapeutics Inc's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Seagate Technology Holdings PLC for 41 Days and TG Therapeutics Inc for 16 Days on average.
| STX | TGTX | |
|---|---|---|
Market Cap | $176.19B | $8.16B |
Volume | 5,061,875 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $1.09K | $59.06 |
52-Week Low | $211.63 | $26.94 |
Typical Hold Time | 41 Days | 16 Days |
Enterprise Value | $178.34B | $8.37B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STX trades at $783, down 3.01% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $5.71 vs. $5.10, and robust profitability metrics including 26.11% net income margin. Technical indicators are bearish with price near pivot point support at $782, while analyst consensus remains positive with 54% buy ratings and $1,130 price target.
Despite near-term competitive pressures, STX maintains strong AI-driven storage demand positioning. Investment opportunity lies in the company's record margins and nearly sold-out capacity, though risks include potential pricing pressure from increased industry supply and high valuation multiples that may limit upside potential.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
